LENZ Share Price Performance
US$5.76
-23.55 (-80.35%)
97.1% undervalued intrinsic discount
US$200.00
Fair Value
Price US$5.76
MotherHorseEyes US$200.00
AnalystHighTarget US$62.00
AnalystLowTarget US$12.00
Fair ValueUS$200.00
Share Pricen/a
LENZ Therapeutics, Inc. Stock Price
- 4 Narratives written by author
- 1 Comments on narratives written by author
- 37 Fair Values set on narratives written by author
LENZ Community Narratives
MO
Fair Value
·Fair Value US$200 97.1% undervalued intrinsic discount
LENZ Therapeutics - a high risk high reward small cap biotech stock
9users have liked this narrative
1users have commented on this narrative
12users have followed this narrative
AN
Fair Value
·Fair Value US$62 90.7% undervalued intrinsic discount
Presbyopia Eye Drop Adoption Will Drive Strong Long Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$12 52.0% undervalued intrinsic discount
Presbyopia Drug Adoption Risks May Limit Returns Yet Long-Term Demand Should Still Support Upside
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
LENZ Therapeutics - a high risk high reward small cap biotech stock
LENZ Therapeutics is betting big on a newly approved eye drop that could help people with age-related trouble reading up close, and it plans to start selling it soon. The upside hinges on whether patients and doctors switch from an existing option—and whether a one-product company can avoid surprises once the drug is widely used.Read more
MO
US$200
97.1% undervalued intrinsic discount
Fair Value
Profit Margin
15.03%
Future PE
25.02x
Price in 2030
US$277.58
Presbyopia Drug Adoption Risks May Limit Returns Yet Long-Term Demand Should Still Support Upside
LENZ is betting that its new eye drop can become a simple, everyday option for people who struggle with close-up vision, not just a one-time try for early users. The big question is whether patients and doctors stick with it long enough to justify heavy marketing spend and a business built around a single product.Read more
AN
US$12
52.0% undervalued intrinsic discount
Fair Value
Profit Margin
19.65%
Future PE
42.25x
Price in 2029
US$14.59
Presbyopia Drug Launch And Consumer Campaign Will Create Long-Term Opportunity
Catalysts About LENZ Therapeutics LENZ Therapeutics is a commercial-stage biopharma company focused on VIZZ, an aceclidine-based eye drop for presbyopia in adults. What are the underlying business or industry changes driving this perspective?Read more
AN
US$53.71
89.3% undervalued intrinsic discount
Fair Value
Profit Margin
13.3%
Future PE
93.18x
Price in 2029
US$65.72
Presbyopia Eye Drop Adoption Will Drive Strong Long Term Upside Potential
Catalysts About LENZ Therapeutics LENZ Therapeutics develops and commercializes innovative ophthalmic therapies, led by VIZZ, a novel eye drop for presbyopia. What are the underlying business or industry changes driving this perspective?Read more
AN
US$62
90.7% undervalued intrinsic discount
Fair Value
Profit Margin
20.87%
Future PE
65.65x
Price in 2028
US$75.86
Trending Discussion
Recently Updated Narratives
MO
LENZ Therapeutics - a high risk high reward small cap biotech stock
Fair Value: US$200 97.1% undervalued intrinsic discount
12 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
LENZ: Presbyopia Partnership And UK Filing Will Drive Future Repricing
Fair Value: US$12 52.0% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Presbyopia Drug Launch And Consumer Campaign Will Create Long-Term Opportunity
Fair Value: US$53.71 89.3% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
LENZ Therapeutics, Inc. Key Details
About LENZ
- Founded
- 2013
- Employees
- 152
- CEO
- WebsiteView website
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
